Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines
© 2023. West China Hospital, Sichuan University..
The role of gut microbiota in modulating the durability of COVID-19 vaccine immunity is yet to be characterised. In this cohort study, we collected blood and stool samples of 121 BNT162b2 and 40 CoronaVac vaccinees at baseline, 1 month, and 6 months post vaccination (p.v.). Neutralisation antibody, plasma cytokine and chemokines were measured and associated with the gut microbiota and metabolome composition. A significantly higher level of neutralising antibody (at 6 months p.v.) was found in BNT162b2 vaccinees who had higher relative abundances of Bifidobacterium adolescentis, Bifidobacterium bifidum, and Roseburia faecis as well as higher concentrations of nicotinic acid (Vitamin B) and γ-Aminobutyric acid (P < 0.05) at baseline. CoronaVac vaccinees with high neutralising antibodies at 6 months p.v. had an increased relative abundance of Phocaeicola dorei, a lower relative abundance of Faecalibacterium prausnitzii, and a higher concentration of L-tryptophan (P < 0.05) at baseline. A higher antibody level at 6 months p.v. was also associated with a higher relative abundance of Dorea formicigenerans at 1 month p.v. among CoronaVac vaccinees (Rho = 0.62, p = 0.001, FDR = 0.123). Of the species altered following vaccination, 79.4% and 42.0% in the CoronaVac and BNT162b2 groups, respectively, recovered at 6 months. Specific to CoronaVac vaccinees, both bacteriome and virome diversity depleted following vaccination and did not recover to baseline at 6 months p.v. (FDR < 0.1). In conclusion, this study identified potential microbiota-based adjuvants that may extend the durability of immune responses to SARS-CoV-2 vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Signal transduction and targeted therapy - 8(2023), 1 vom: 25. Sept., Seite 373 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peng, Ye [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 17.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41392-023-01629-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362398518 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362398518 | ||
| 003 | DE-627 | ||
| 005 | 20231226091145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41392-023-01629-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362398518 | ||
| 035 | |a (NLM)37743379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peng, Ye |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 17.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. West China Hospital, Sichuan University. | ||
| 520 | |a The role of gut microbiota in modulating the durability of COVID-19 vaccine immunity is yet to be characterised. In this cohort study, we collected blood and stool samples of 121 BNT162b2 and 40 CoronaVac vaccinees at baseline, 1 month, and 6 months post vaccination (p.v.). Neutralisation antibody, plasma cytokine and chemokines were measured and associated with the gut microbiota and metabolome composition. A significantly higher level of neutralising antibody (at 6 months p.v.) was found in BNT162b2 vaccinees who had higher relative abundances of Bifidobacterium adolescentis, Bifidobacterium bifidum, and Roseburia faecis as well as higher concentrations of nicotinic acid (Vitamin B) and γ-Aminobutyric acid (P < 0.05) at baseline. CoronaVac vaccinees with high neutralising antibodies at 6 months p.v. had an increased relative abundance of Phocaeicola dorei, a lower relative abundance of Faecalibacterium prausnitzii, and a higher concentration of L-tryptophan (P < 0.05) at baseline. A higher antibody level at 6 months p.v. was also associated with a higher relative abundance of Dorea formicigenerans at 1 month p.v. among CoronaVac vaccinees (Rho = 0.62, p = 0.001, FDR = 0.123). Of the species altered following vaccination, 79.4% and 42.0% in the CoronaVac and BNT162b2 groups, respectively, recovered at 6 months. Specific to CoronaVac vaccinees, both bacteriome and virome diversity depleted following vaccination and did not recover to baseline at 6 months p.v. (FDR < 0.1). In conclusion, this study identified potential microbiota-based adjuvants that may extend the durability of immune responses to SARS-CoV-2 vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a sinovac COVID-19 vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Zhang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Mok, Chris K P |e verfasserin |4 aut | |
| 700 | 1 | |a Ching, Jessica Y L |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Shilin |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Matthew K L |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chunke |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shilan |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Biyan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Chun Pun |e verfasserin |4 aut | |
| 700 | 1 | |a Cheong, Pui Kuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ip, Ka Long |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Adrian C H |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Kenneth K Y |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, David S C |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Francis K L |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Siew C |e verfasserin |4 aut | |
| 700 | 1 | |a Tun, Hein M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 8(2023), 1 vom: 25. Sept., Seite 373 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:1 |g day:25 |g month:09 |g pages:373 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-023-01629-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 1 |b 25 |c 09 |h 373 | ||